TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07776782: A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants

Sponsor: Mirador Therapeutics, Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 25 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$6,366,432

Rescue Site Savings

+$4,199,136

Unlock Full NCT07776782 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07776782 Rescue Dossier →